SCANCELL HLDGS (SCLP)

 

SCANCELL HLDGS (SCLP.L, LSE, LSE:SCLP)

SCLP Share PerformanceMore

52 week high45.240 01/06/15
52 week low22.435 02/04/15
52 week change -7.250 (-21.48%)
4 week volume3,469,330 05/08/15

Media for (SCLP)

Presenter: Dr Richard Goodfellow
31/07/2015
Presenter: Dr Richard Goodfellow
02/06/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Notice of AGM

RNS Number: 3587X Scancell Holdings Plc 27 August 2015 27 August 2015 Scancell Holdings Plc Notice of AGM Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting on Tuesday 20 October 2015. AGM details are as follows: Date: Tuesday 20 October, 2015 Time: 11.00...

General update and collaboration with ImmunID

Collaboration with ImmunID

RNS Number: 5007U Scancell Holdings Plc 30 July 2015 Scancell and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCkeR Nottingham, UK and Grenoble, France, 30 July 2015 - Scancell Holdings plc ('Scancell' LSE:AIM SCLP), the developer of novel immunotherapies for the treatment of cancer, and ImmunID, an immune molecular ...

Scancell says patient recruitment completed for SCIB1 trial

Scancell Holdings has closed patient recruitment for its SCIB1 ImmunoBody Phase 1/2 clinical trial in patients with Stage II...

Patient recruitment completed for SCIB1 trial

RNS Number: 5588S Scancell Holdings Plc 09 July 2015 09 July 2015 Scancell Holdings Plc Patient recruitment completed for SCIB1 Phase 1/2 clinical trial SCIB1 continues to deliver strong survival data in resected melanoma patients with Stage III/IV disease Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of ...

Is Scancell Holdings Plc The Perfect Partner For BTG plc And Shire PLC In Your Portfolio?

Shares in pharmaceutical company, Scancell (LSE:SCLP), have fallen by as much as 10% today despite the company provid...

Scancell provides positive update on SCIB1 data

Scancell Holdings confirms further encouraging results from its on-going Phase 1/2 clinical trial of SCIB1, its DNA Immun...

SCIB1 data update in resected melanoma patients

RNS Number: 8686O Scancell Holdings Plc 02 June 2015 2 June 2015 Scancell Holdings Plc Scancell provides positive update on SCIB1 data in resected melanoma patients Median survival time of 34 and 31 months for Stage III and IV patients Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, is pleased...